Contract development and manufacturing organization (CDMO) for pharmaceuticals, with plants in Taiwan and North America.
Contract development and manufacturing organization (CDMO) for pharmaceuticals, with plants in Taiwan and North America.
Paid by drugmakers under development and manufacturing contracts, so revenue rests on a limited number of multi-year client relationships. Its North American plants, bought from other drug companies, put capacity close to US customers.
In one line: A small-cap Catalent.
Moat: narrow (regulatory licence, switching costs, process know-how). FDA-approved plants and multi-year manufacturing contracts are costly for clients to re-qualify.
Headquarters: Taipei, Taiwan
Size Bora Pharmaceuticals (6472.TW) is a Taiwan Health Care company (Pharmaceuticals: Other) with a market value of $1.25B, the 225th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$344.50 on 18 Nov 2026.
Performance Over six months the shares fell 2.4%, against -9.8% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 6.5% over the last twelve months (peer median +9.1%); the operating margin is 14.3% (peer median 15.9%).
Valuation It trades at 10.8× forward earnings against a peer median of 20.6× (4th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +60%, so the hurdle is -57 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.0 points above its cost of capital (5.0% WACC).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$21.2B | NT$19.0B | NT$17.4B | NT$14.2B | NT$10.5B |
| Revenue growth | — | +9% | +23% | +35% | — |
| Gross profit | NT$7.91B | NT$7.66B | NT$7.63B | NT$6.91B | NT$2.86B |
| EBITDA | NT$4.32B | NT$4.23B | NT$4.56B | NT$5.85B | NT$2.25B |
| Net income | NT$1.53B | NT$2.98B | NT$3.85B | NT$3.03B | NT$1.39B |
| Free cash flow | NT$2.42B | NT$3.31B | NT$83.0M | NT$4.16B | NT$1.72B |
| Capital expenditure | NT$2.04B | NT$1.01B | NT$856M | NT$1.43B | NT$215M |
| Total debt | NT$25.7B | NT$18.2B | NT$19.0B | NT$5.01B | NT$7.60B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bora Pharmaceuticals 6472.TW | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% |
| Lonza LONN.SW | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% |
| Siegfried SFZN.SW | $3.51B | -17% | +4% | 16% | 16.8× | n/a |
| PharmaEssentia 6446.TW | $15.0B | +67% | +78% | 40% | 31.9× | 23.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6472.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.0% | -2.3% | lowest of 21 |
| 6-month return | -2.4% | -9.8% | 8th highest of 21 |
| Distance from 52-week high | -47.1% | -29.8% | 3rd lowest of 21 |
| Revenue growth (TTM) | +6.5% | +9.1% | 11th highest of 21 |
| Operating margin | 14.3% | 15.9% | 10th lowest of 21 |
| Forward P/E | 10.8× | 20.6× | 4th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 3.5% | 7.7% | 8th least demanding of 17 |
| Growth delivered (Del g) | +60.2% | +12.0% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | -56.8 pp | -8.8 pp | least demanding of 17 |
| ROIC minus cost of capital | +1.0 pp | +2.7 pp | 8th lowest of 21 |
| EV / EBITDA | 14.7× | 18.2× | 4th cheapest of 11 |
| Net debt / EBITDA | 4.6× | -1.1× | most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% | +60.2% |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 31.0× | 1.5% | +15.5% |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 41.4× | 10.6% | -3.9% |
| Jamieson Wellness JWEL.TO | Canada | $1.32B | +32% | +12% | 13% | 20.6× | 13.5% | +15.3% |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 11.7× | 13.1% | +62.3% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.45B | +85% | +27% | 33% | 69.1× | n/a | n/a |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.05B | -12% | -3% | 24% | 12.8× | -8.7% | +5.5% |
| Zhejiang Medicine 600216.SS | China | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% | +3.9% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.03B | -19% | -1% | 4% | 6.2× | -2.1% | +7.1% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.58B | -17% | -7% | 28% | n/a | -1.9% | +10.4% |
| Applied Nutrition APN.L | United Kingdom | $986M | +31% | +51% | 25% | 21.4× | 24.6% | +38.5% |
| Porton Pharma Solutions 300363.SZ | China | $1.66B | +37% | +6% | -2% | n/a | 2.1% | +10.4% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $942M | -18% | -14% | 8% | 182.0× | n/a | n/a |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 33.5× | 4.7% | +18.5% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $856M | -34% | +30% | 15% | 8.7× | n/a | n/a |
| TSI 603262.SS | China | $842M | -46% | +3% | 14% | 47.7× | 24.3% | +13.4% |
| China Meheco 600056.SS | China | $1.90B | -16% | +2% | 3% | n/a | -1.3% | -2.1% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $760M | -8% | -18% | 25% | 7.6× | n/a | n/a |
| Sirio Pharma 300791.SZ | China | $759M | -6% | -9% | 1% | 16.2× | 14.1% | +15.6% |
| Granules India GRANULES.NS | India | $2.12B | +4% | +22% | 17% | 24.8× | 23.6% | +10.6% |